Yahoo Finance

Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS

EMERYVILLE, Calif., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Yahoo Finance

Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025

EMERYVILLE, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with ...
Business Insider

Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma

The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...
Nasdaq

Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome

The application was evaluated based on the positive clinical outcomes of KYV-101 in patients treated in Germany under a named-patient treatment option The Regenerative Medicine Advanced Therapies ...
Healio

Patient with lupus treated with KYV-101 CAR T-cell therapy relapses after 5 months

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A patient with lupus nephritis who received KYV-101 ...
NDTV

Fastag Kyv

NHAI to discontinue mandatory KYV for new car FASTags from Feb 1, 2026, easing activation hassles and improving user convenience. The National Highways Authority of India (NHAI) recently announced the ...
Mena FN

Kyverna Therapeutics Highlights Potential Of KYV-101 In Rheumatoid Arthritis With Phase 1 Data From Investigator-Initiated Trial Presented At ACR Convergence 2025

(MENAFN- GlobeNewsWire - Nasdaq) KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis ...